Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024603 · ClinicalTrials.gov registry record · NA
Individualized Treatments in Adults With Relapsed/Refractory Cancers
A NA study of Refractory Cancer and Relapsed Cancer, sponsored by Case Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT06024603: Active NA study of Refractory Cancer and Relapsed Cancer, sponsored by Case Comprehensive Cancer Center.
NCT06024603 is a NA study of Refractory Cancer and Relapsed Cancer that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 36 participants, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06024603, a NA study of Refractory Cancer and Relapsed Cancer, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.
Primary Outcome
Primary objective is to determine feasibility of providing treatment recommendations to relapsed and refractory adult cancer patients based on ex vivo drug sensitivity testing (DST). Feasibility will be demonstrated if it is possible to recommend treatment within 4 weeks in at least 22 of 36 participants (62.5%).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Drug Sensitivity Test (DST)
Study Locations (2)
Florida
- Florida International University - Miami
- Lerner College of Medicine, Cleveland Clinic Florida - Weston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT06024603 still lists
NCT06024603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Refractory Cancer appearing as the primary indexed condition, and to 1 intervention - of which Drug Sensitivity Test (DST) is the first listed.
NCT06024603 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06024603 about?
NCT06024603 is a clinical study titled "Individualized Treatments in Adults With Relapsed/Refractory Cancers". A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type...
What is the current status of trial NCT06024603?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2023-11-20. Estimated completion is 2026-06.
What conditions does trial NCT06024603 study?
This clinical trial studies the following conditions: Refractory Cancer, Relapsed Cancer.
What interventions are being tested in trial NCT06024603?
The interventions under investigation include: Drug Sensitivity Test (DST) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06024603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06024603 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06024603's enrollment target sits among peer trials
36 11th of 15 higher than 5 of 15 other Refractory Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI